GGrantIndex
← Leaderboards

Steffi Oesterreich

Baylor College Of Medicine

$10,632,097
Attributed
$13,428,318
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,779,466 · 11

By mechanism

R01$11,456,396 · 5
P01$8,494,503 · 2
R21$417,731 · 1
K01$397,836 · 1
R13$13,000 · 2

Top collaborators

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Breast Neoplasm

Research focus

Malignant Breast NeoplasmEstrogen ReceptorsResponseIn VivoGenesEndocrineIn VitroResistanceBreast Cancer Cell LineCell LineBreast Cancer CellEstrogensEstrogen Receptor PositiveCellsMalignant NeoplasmsHormone TherapyMolecularHormonesTumorMutationHistologicNeoplasm MetastasisRecurrenceGrowth

Grant awards (46)

Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$579,181
R01 · FY2025 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$527,799
R01 · FY2025 · CA · contact PI
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$550,223
R01 · FY2024 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$355,698
R01 · FY2024 · CA · contact PI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$570,252
R01 · FY2023 · CA · contact PI
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$567,598
R01 · FY2023 · CA
Developing and credentialing murine models of ILC$148,387
R01 · FY2023 · CA · contact PI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$568,084
R01 · FY2022 · CA · contact PI
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$565,878
R01 · FY2022 · CA
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer$385,984
R01 · FY2022 · CA · contact PI
FGFR4: A druggable mediator of endocrine resistance in breast cancer$347,404
R01 · FY2022 · CA · contact PI
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer$586,301
R01 · FY2021 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research$573,041
R01 · FY2021 · CA · contact PI
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer$393,861
R01 · FY2021 · CA · contact PI
FGFR4: A druggable mediator of endocrine resistance in breast cancer$354,536
R01 · FY2021 · CA · contact PI
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer$393,861
R01 · FY2020 · CA · contact PI
FGFR4: A druggable mediator of endocrine resistance in breast cancer$354,577
R01 · FY2020 · CA · contact PI
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer$382,045
R01 · FY2019 · CA · contact PI
FGFR4: A druggable mediator of endocrine resistance in breast cancer$343,977
R01 · FY2019 · CA · contact PI
2019 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar$7,000
R13 · FY2019 · CA · contact PI
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer$407,387
R01 · FY2018 · CA · contact PI
FGFR4: A druggable mediator of endocrine resistance in breast cancer$353,354
R01 · FY2018 · CA · contact PI
International Symposium on Lobular Breast Cancer$6,000
R13 · FY2016 · CA · contact PI
ER Co-repressor function of SAFB in Breast Cancer$293,910
R01 · FY2012 · CA · contact PI
ER Co-repressor function of SAFB in Breast Cancer$293,910
R01 · FY2011 · CA · contact PI
A functional SRC1 SNP in bone biology$187,481
R21 · FY2011 · DK · contact PI
A functional SRC1 SNP in bone biology$230,250
R21 · FY2010 · DK · contact PI
ER Co-repressor function of SAFB in Breast Cancer$203,529
R01 · FY2010 · CA · contact PI
ER Co-repressor function of SAFB in Breast Cancer$49,129
R01 · FY2010 · CA · contact PI
ER Co-repressor function of SAFB in Breast Cancer$274,812
R01 · FY2009 · CA · contact PI
Novel Gene Networks in Breast Development and Cancer$176,495
P01 · FY2009 · CA · contact PI
Novel Gene Networks in Breast Development and Cancer$2,398,875
P01 · FY2008 · CA · contact PI
Scaffold Attachment Factors SAFB1 /2 as Novel Breast Tumor Suppressor Genes$300,119
P01 · FY2008 · CA · contact PI
Novel Gene Networks in Breast Development and Cancer$2,383,667
P01 · FY2007 · CA · contact PI
Scaffold Attachment Factors SAFB1 /2 as Novel Breast Tumor Suppressor Genes$297,290
P01 · FY2007 · CA · contact PI
Novel Gene Networks in Breast Development and Cancer$2,392,111
P01 · FY2006 · CA · contact PI
SAFB1 /2 Factors as Noval Breast Tumor Suppressor Genes$186,460
P01 · FY2006 · CA · contact PI
ER Co-Repressor Function of SAFB in Breast Cancer$267,890
R01 · FY2005 · CA
SAFB1 /2 Factors as Noval Breast Tumor Suppressor Genes$181,030
P01 · FY2005 · CA
ER Co-Repressor Function of SAFB in Breast Cancer$267,890
R01 · FY2004 · CA
SAFB1 /2 Factors as Noval Breast Tumor Suppressor Genes$178,456
P01 · FY2004 · CA
ER Co-Repressor Function of SAFB in Breast Cancer$267,890
R01 · FY2003 · CA
ER Co-Repressor Function of SAFB in Breast Cancer$228,008
R01 · FY2002 · CA
NEW NUCLEAR MATRIX PROTEIN IN BREAST CANCER GROWTH$135,360
K01 · FY2002 · CA
NEW NUCLEAR MATRIX PROTEIN IN BREAST CANCER GROWTH$132,675
K01 · FY2001 · CA
NEW NUCLEAR MATRIX PROTEIN IN BREAST CANCER GROWTH$129,801
K01 · FY2000 · CA